In this population-based cohort study, we observed that ADRB2 polymorphisms: rs1042713 and rs1042714 were associated with a reduced risk of COPD exacerbation in current users of inhaled β2-agonists. Here, ADRB2 is linked to chronic obstructive pulmonary disease.